CoChat

The Contribution of GWAS Loci in Familial Dyslipidemias

Open access

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

Familial combined hyperlipidemia (FCH) is a complex and common familial dyslipidemia characterized by elevated total cholesterol and/or triglyceride levels with over five-fold risk of coronary heart disease. The genetic architecture and contribution of rare Mendelian and common variants to FCH susceptibility is unknown. In 53 Finnish FCH families, we genotyped and imputed nine million variants in 715 family members with DNA available. We studied the enrichment of variants previously implicated with monogenic dyslipidemias and/or lipid levels in the general population by comparing allele frequencies between the FCH families and population samples. We also constructed weighted polygenic scores using 212 lipid-associated SNPs and estimated the relative contributions of Mendelian variants and polygenic scores to the risk of FCH in the families. We identified, across the whole allele frequency spectrum, an enrichment of variants known to elevate, and a deficiency of variants known to lower LDL-C and/or TG levels among both probands and affected FCH individuals. The score based on TG associated SNPs was particularly high among affected individuals compared to non-affected family members. Out of 234 affected FCH individuals across the families, seven (3%) carried Mendelian variants and 83 (35%) showed high accumulation of either known LDL-C or TG elevating variants by having either polygenic score over the 90th percentile in the population. The positive predictive value of high score was much higher for affected FCH individuals than for similar sporadic cases in the population. FCH is highly polygenic, supporting the hypothesis that variants across the whole allele frequency spectrum contribute to this complex familial trait. Polygenic SNP panels improve identification of individuals affected with FCH, but their clinical utility remains to be defined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1006078

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Distributions of lipid levels in subsets of the Finnish general population and the FCH samples. Distributions of (a) LDL-C and (b) TG are shown for the Finnish FINRISK population cohort (FINRISK all, blue), hyperlipidemic Finnish population samples (FINRISK hyperlipidemic, green), all FCH family members (FCH all, brown), affected family members (FCH affected, red), and proband individuals (FCH probands, purple). Hyperlipidemia in the population samples is defined as TC or TG ≥ 90th age- and sex-specific population percentile, analogously with the FCH diagnostic criteria. In (b) the x-axis is cut at 9 mmol/l. FCH, familial combined hyperlipidemia; FINRISK, The National FINRISK Study.
Fig 1 Distributions of lipid levels in subsets of the Finnish general population and the FCH samples. Distributions of (a) LDL-C and (b) TG are shown for the Finnish FINRISK population cohort (FINRISK all, blue), hyperlipidemic Finnish population samples (FINRISK hyperlipidemic, green), all FCH family members (FCH all, brown), affected family members (FCH affected, red), and proband individuals (FCH probands, purple). Hyperlipidemia in the population samples is defined as TC or TG ≥ 90th age- and sex-specific population percentile, analogously with the FCH diagnostic criteria. In (b) the x-axis is cut at 9 mmol/l. FCH, familial combined hyperlipidemia; FINRISK, The National FINRISK Study.CC BY · PubMed Central
Fig 2 Enrichment of LDL-C or TG associated SNPs in FCH affected individuals by their frequency and effect on LDL-C and TG levels. Enrichment ratio is the ratio of the allele frequencies in the affected individuals (n = 234) to the allele frequencies in the Finnish FINRISK population cohort (n = 18,715). Only individuals without diabetes or other relevant confounders were included (S1 Text). Under the null hypothesis of no enrichment, a 95% credible interval (shaded area) was estimated by calculating the enrichment statistic (enrichment ratio) for all variants with MAF > 0.001% across the genome excluding the loci of the 212 SNPs. Variants are designated as either lipid level elevating (red) or lowering (blue) for (a) LDL-C and (b) TG based on β estimates from linear regression in the FINRISK samples. Point size and color intensity reflect the magnitude of the effect. Only SNPs with at least one heterozygous carrier are shown (n = 194). *The enrichment ratio for LPL rs1801177 fell within the 95% credible interval.
Fig 2 Enrichment of LDL-C or TG associated SNPs in FCH affected individuals by their frequency and effect on LDL-C and TG levels. Enrichment ratio is the ratio of the allele frequencies in the affected individuals (n = 234) to the allele frequencies in the Finnish FINRISK population cohort (n = 18,715). Only individuals without diabetes or other relevant confounders were included (S1 Text). Under the null hypothesis of no enrichment, a 95% credible interval (shaded area) was estimated by calculating the enrichment statistic (enrichment ratio) for all variants with MAF > 0.001% across the genome excluding the loci of the 212 SNPs. Variants are designated as either lipid level elevating (red) or lowering (blue) for (a) LDL-C and (b) TG based on β estimates from linear regression in the FINRISK samples. Point size and color intensity reflect the magnitude of the effect. Only SNPs with at least one heterozygous carrier are shown (n = 194). *The enrichment ratio for LPL rs1801177 fell within the 95% credible interval.CC BY · PubMed Central
Fig 3 Number of affected and unaffected individuals with high polygenic lipid scores or carriers of high-impact Mendelian variants. The black shading presents the number of (a) affected, and (b) unaffected individuals with high polygenic lipid scores (LDL-C, TG, or both polygenic scores over the 90th percentile in the population) or carriers of a high-impact Mendelian variant (APOE ɛ2ɛ2, n = 2; or homozygosity for APOA5 rs3135506). The families are sorted by the number of affected individuals with high polygenic lipid scores or a high-impact Mendelian variant in (a). The grey shading presents the number of other (a) affected, and (b) unaffected individuals in the family.
Fig 3 Number of affected and unaffected individuals with high polygenic lipid scores or carriers of high-impact Mendelian variants. The black shading presents the number of (a) affected, and (b) unaffected individuals with high polygenic lipid scores (LDL-C, TG, or both polygenic scores over the 90th percentile in the population) or carriers of a high-impact Mendelian variant (APOE ɛ2ɛ2, n = 2; or homozygosity for APOA5 rs3135506). The families are sorted by the number of affected individuals with high polygenic lipid scores or a high-impact Mendelian variant in (a). The grey shading presents the number of other (a) affected, and (b) unaffected individuals in the family.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 60

Metadata

Authors
Ripatti, P., Rämö, J. T., Söderlund, S., Surakka, I., Matikainen, N., Pirinen, M., Pajukanta, P., Sarin, A.-P., Service, S. K., Laurila, P.-P., Ehnholm, C., Salomaa, V., Wilson, R. K., Palotie, A., Freimer, N. B., Taskinen, M.-R., & Ripatti, S.
Affiliations
  • University of Helsinki (FI)
  • Broad Institute (US)
  • University of California, Los Angeles (US)
  • Finnish Institute for Health and Welfare (FI)
  • Washington University in St. Louis (US)
Corresponding author
Ripatti, Samuli
Venue
PLOS Genetics
Published
2016-05-26
Volume
12
Issue
5
Pages
e1006078
ISSN
  • 1553-7390 (ISSN-L)
  • 1553-7404
OpenAlex
W2289474097
Cited by
60
References
30
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 1 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 10 · 2018: 10 · 2017: 4 · 2016: 2
FWCI
6.99
Type
journal article
Language
en
Open access
Locations
  • PLoS Genetics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
Funders
  • National Institutes of Health (HL113315, HL095056, HL28481)
  • Sydäntutkimussäätiö
  • Sigrid Juséliuksen Säätiö
  • Biocentrum Helsinki
  • EU 7th Framework Program (305707)
  • Helsinki University Central Hospital Fund
  • University of Helsinki Jubilee Fund
  • Helsingin Yliopisto
  • Suomen Lääketieteen Säätiö
  • Emil Aaltosen Säätiö
  • Biomedicum Helsinki-säätiö
  • Suomen Akatemia (251217)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
familial combined hyperlipidemia, familial dyslipidemia, polygenic risk score, allele frequency spectrum, triglycerides, LDL cholesterol, genetic architecture, coronary heart disease risk, Finnish families
MeSH terms
Adult, Apolipoproteins B, Coronary Artery Disease, Female, Humans, Hyperlipidemia, Familial Combined, Cholesterol, HDL, Lipoproteins, LDL, Male, Middle Aged, Triglycerides, Dyslipidemias, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Contribution of GWAS Loci in Familial Dyslipidemias. https://app.cochat.ai/papers/10.1371/journal.pgen.1006078
The paper
Ripatti, P., Rämö, J. T., Söderlund, S., Surakka, I., Matikainen, N., Pirinen, M., Pajukanta, P., Sarin, A.-P., Service, S. K., Laurila, P.-P., Ehnholm, C., Salomaa, V., Wilson, R. K., Palotie, A., Freimer, N. B., Taskinen, M.-R., & Ripatti, S. (2016). The Contribution of GWAS Loci in Familial Dyslipidemias. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1006078

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.